Table 2 Comparison of clinical characteristics between NSCLCs harboring classic activating EGFR mutations and EGFR exon 18 mutations.
Variables | Classic activating | Mutations in | p |
|---|---|---|---|
mutations | exon 18 | ||
| Ā | (nā=ā661) | (nā=ā34) | Ā |
Gender | |||
āFemale | 420 (63.5%) | 27 (79.4%) | Ā |
āMale | 241 (36.5%) | 7 (20.6%) | 0.067 |
Age (y) | |||
āMean | 60.0 | 60.9 | Ā |
āSD | 10.0 | 11.5 | 0.652 |
Smoking history | |||
āEver | 140 (21.2%) | 4 (11.8%) | Ā |
āNever | 521 (78.8%) | 30 (88.2%) | 0.276 |
Tumor size (cm) | |||
āā¤3 | 518 (78.4%) | 23 (67.6%) | Ā |
ā>3 | 143 (21.6%) | 11 (32.4%) | 0.143 |
Stage | |||
āI | 388 (58.7%) | 19 (55.9%) | Ā |
āIIāIV | 273 (41.3%) | 15 (44.1%) | 0.859 |
Differentiation | |||
āWell/Moderate | 522 (79.0%) | 22 (64.7%) | Ā |
āPoor | 139 (21.0%) | 12 (35.3%) | 0.056 |
